ウパダシチニブ化学構造式

ウパダシチニブ

化学名:ウパダシチニブ

CAS番号.1310726-60-3

英語名:Upadacitinib

CBNumberCB53121345

MFC17H19F3N6O

MW380.37

MOL File1310726-60-3.mol

别名

ウパダシチニブ

ウパダシチニブ水和物

N-(2,2,2-トリフルオロエチル)-3β-エチル-4β-(3H-4,6,8a-トリアザシクロペンタ[e]インドール-8-イル)ピロリジン-1-カルボアミド

ウパダシチニブ物理性質

比重(密度)	1.56±0.1 g/cm3(Predicted)
貯蔵温度	Store at -20°C
溶解性	DMSO:42.67(Max Conc. mg/mL);112.17(Max Conc. mM) DMSO:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.31(Max Conc. mM) DMF:30.0(Max Conc. mg/mL);78.87(Max Conc. mM) Ethanol:76.0(Max Conc. mg/mL);199.8(Max Conc. mM)
外見	A crystalline solid
酸解離定数(Pka)	11.89±0.60(Predicted)
色	White to off-white
InChI	InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
InChIKey	WYQFJHHDOKWSHR-MNOVXSKESA-N
SMILES	N1(C(NCC(F)(F)F)=O)C[C@H](C2N3C4C=CNC=4N=CC3=NC=2)[C@H](CC)C1

危険有害性情報のコード(GHS)

ウパダシチニブ化学特性,用途語,生産方法

効能
抗リウマチ薬, ヤヌスキナーゼ(JAK)阻害薬
特性
Class: non-receptor tyrosine kinase
Treatment: psoriatic arthritis, rheumatoid arthritis
Elimination half-life = 6–16 h
Protein binding = 52%
使用
Upadacitinib also known as ABT-494, is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders, Janus kinase inhibitors for rheumatoid arthritis. It is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, and moderate to severe Crohn's disease in patients who have taken other medicines (eg, methotrexate) that did not work well. It is also used to treat moderate to severe atopic dermatitis (eczema) in patients who have taken other medicines that did not work well and whose condition is not well controlled with other treatments or in patients who cannot tolerate these treatments. It is also used to treatpsoriatic arthritis, axial SpA and Giant Cell Arteritis and Takayasu Arteritis.
brand name
Upadacitinib is marketed under the brand name RINVOQ for oral administration.
生物活性
Upadacitinib is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib can be used for several autoimmune disorders research. In vivo, Upadacitinib inhibited paw swelling and bone destruction in a rat model of arthritis.
作用機序
The Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases whose function is to transduce cytokine-mediated signals via the JAK-STAT pathway. There are four JAK subtypes, each of which has overlapping receptor responsibilities. Inhibitors of this enzyme family (jakinibs) have shown efficacy in treating certain inflammatory and autoimmune diseases such as rheumatoid arthritis and Crohn's disease. However, the first generation of these drugs, tofacitinib and ruxolitinib, lacked subtype selectivity, affecting JAK1/JAK3 and JAK1/JAK2 respectively. This has led to dose-limiting side effects in this otherwise promising class of drugs. Upadacitinib is a second generation Janus kinase inhibitor that is selective for the JAK1 subtype of this enzyme over the JAK2 (74-fold), JAK3 (58-fold) and tyrosine kinase 2 subtypes.
臨床応用
Upadacitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.
副作用
Common side effects are upper respiratory tract infections such as common cold and sinus infections (13.5% of patients in studies), nausea (3.5%), cough (2.2%), fever, and increased liver enzymes. Serious side effects include infections, including life-threatening ones, such as pneumonia, cellulitis, tuberculosis, as well as shingles and other herpes infections.
代謝
Upadacitinib displays a dose-proportional pharmacokinetic profile over the therapeutic dose range. Following oral administration, the median time to reach Cmax (Tmax) ranges from 2 to 4 hours. The steady-state plasma concentrations of upadacitinib are reached within 4 days following multiple once-daily administrations, with minimal accumulation. Food intake has no clinically relevant effect on the AUC, Cmax, and Cmin of upadacitinib from the extended-release formulation. Upadacitinib metabolism is mainly mediated by CYP3A4, with a potential minor contribution from CYP2D6. Administration of strong CYP3A inhibitors increases upadacitinib AUC by 75% and Cmax by 70%, while strong inducers of CYP3A reduce upadacitinib plasma exposures by approximately half[1].

ウパダシチニブ上流と下流の製品情報

ウパダシチニブ生産企業

ウパダシチニブスペクトルデータ(¹HNMR)

1310726-60-3, ウパダシチニブキーワード

Send Inquriy

ウパダシチニブ

危険有害性情報のコード(GHS)

ウパダシチニブ 化学特性,用途語,生産方法

ウパダシチニブ 上流と下流の製品情報

ウパダシチニブ 生産企業

ウパダシチニブ スペクトルデータ(1HNMR)

1310726-60-3, ウパダシチニブ キーワード

ウパダシチニブ化学特性,用途語,生産方法

ウパダシチニブ上流と下流の製品情報

ウパダシチニブ生産企業

ウパダシチニブスペクトルデータ(¹HNMR)

1310726-60-3, ウパダシチニブキーワード